Media Centre
News Article

COVID-19 vaccines were not developed overnight “humanity was lucky” — Guyanese virologist at Pfizer

September 2, 2021

Principal Research Scientist at the United States drug maker Pfizer, Dr Vidia Roopchand, has sought to dispel concerns that COVID vaccines were developed overnight but said they date back to the fight against two other coronaviruses.

He said research in tackling Severe Acute Respiratory Syndrome (SARS) in the early 2000s and Middle Eastern Respiratory Syndrome (MERS) in 2012 formed the basis for developing vaccines for COVID-19.

“A lot of people don’t realise this, but people have been working on coronaviruses for at least the last 20 years because the first SARS came out in 2001, so people have been working on a spike for SARS and other coronaviruses for a long time… so SARS and MERS allowed us, meaning the virology community,…to make all of these structural substitutions,” he said.

Speaking on a University of Guyana (UG)-organised webinar on the topic “SARS COV-2 (Covid-19) Viral Physiology and Vaccine Development”, he explained that coronaviruses, including many of the common cold viruses, have been infecting humans for a long time. They include the Human coronavirus HKU1 (HCoV-HKU1), which has been causing respiratory problems for many years.

“People have been studying coronaviruses for a while, but when SARS occurred, people started taking notice, and around that time, there was a revolution in structural biology,” he said, adding that the technology advanced in making images of crystals. He said after MERS came on the scene, scientists said coronaviruses were not as innocuous as they used to think, resulting in them being able to examine gene and protein sequences.

He said the evidence shows that the Pfizer jab is neutralising the Delta variant, even as he urged more people to be inoculated to reduce the chance of other variants. Dr Roopchand urged people to visit the United States Food and Drug Administration’s website to examine the data on the vaccine.

The Virologist said the Pfizer-BioNTech vaccine comprises an RNA sequence, lipids, some salt, sugars, and other constituents.

He said the United States Food and Drug Administration (FDA) had granted Emergency Use Authorisation, based on the efficacy, even as trials continued. The FDA has since granted full authorisation for adults, while emergency authorisation continues for children from 12 years upwards. The US government recently donated 146,000 doses of the Pfizer jab for inoculating mainly adolescents as part of a “back-to-classroom” plan from September 6, 2021.

While there is a perception among some persons that scientists do not believe in God, he stressed that “I do believe in God and I think that something like this makes me believe in God even more because everything works and we were able to make this vaccine.”

The Principal Researcher at Pfizer said the efficacy of the polio vaccine lasts a lifetime because the entire virus had been used for that vaccine, but RNA was now being used for the first time in the manufacture of a COVID-19 vaccine.

Dr Persaud received his early education at the Methodist Primary on Wakenaam Island, Essequibo River and then the Anna Regina Multilateral School before going to the University of Guyana. He later obtained higher qualifications in Chemical Engineering from Columbia University.

WHAT IS PANCAP?

PANCAP is a Caribbean regional partnership of governments, regional civil society organisations, regional institutions and organisations, bilateral and multilateral agencies and contributing donor partners established on 14 February 2001.  PANCAP provides a structured and unified approach to the Caribbean’s response to the HIV epidemic, and coordinates the response through the Caribbean Regional Strategic Framework on HIV and AIDS to maximise efficient use of resources and increase impact, mobilise resources and build the capacity of partners.

What are the Global AIDS Strategy 2021–2026 targets and commitments?

If targets and commitments in the strategy are achieved:

  • The number of people who newly acquire HIV will decrease from 1.7 million in 2019 to less than 370 000 by 2025
  • The number of people dying from AIDS-related illnesses will decrease from 690 000 in 2019 to less than 250 000 in 2025.
  • The goal of eliminating new HIV infections among children will see the number of new HIV infections drop from 150,000 in 2019 to less than 22,000 in 2025.

What are the 95-95-95 Targets for ending AIDS?

  • 95% of People Living with HIV know their HIV status;
  • 95% of people who know their status on treatment; and
  • 95% of people on treatment with suppressed viral loads.

HELPFUL LINKS:

Global AIDS Strategy 2021–2026, End Inequalities, End AIDS
https://pancap.org/pancap-documents/global-aids-strategy-2021-2026-end-inequalities-end-aids/

Caribbean Regional Strategic Framework on HIV and AIDS (CRSF) 2019-2025
https://pancap.org/pancap-documents/caribbean-regional-strategic-framework-2019-2025/